Form 4: Century Therapeutics Executive Chad Cowan Reports Stock and Option Grant

Chad Cowan, Chief Scientific Officer of Century Therapeutics, reports the acquisition of restricted stock units and stock options.

Summary

• Chad Cowan, the Chief Scientific Officer of Century Therapeutics, filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
• On March 11, 2025, Cowan was granted 19,500 restricted stock units (RSUs), each representing a contingent right to receive one share of Century Therapeutics common stock.
• These RSUs vest 25% on March 11, 2026, and the remaining 75% vest quarterly over the following three years, contingent upon Cowan's continued service.
• Cowan also acquired stock options for 19,500 shares with an exercise price of $0.601.
• These options vest 25% on March 11, 2026, with the remaining 75% vesting in 36 equal monthly installments, also subject to continued service.
• Following these transactions, Cowan directly owns 230,306 shares of common stock and indirectly owns 10,697 shares through the Cowan Investment Nominee Trust.
• Cowan disclaims beneficial ownership of the shares held by the trust except to the extent of any pecuniary interest.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The document reflects standard executive compensation practices, which are generally viewed favorably as they align management interests with shareholders. There are no indications of negative news or concerns.

Positives

• The grant of RSUs and stock options to the Chief Scientific Officer aligns his interests with those of the shareholders.
• The vesting schedules of the RSUs and stock options incentivize continued service and commitment from the executive.

Future Outlook

The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into the holdings of company insiders. This filing is typical for companies that use equity-based compensation to incentivize their executives.

Comparison to Industry Standards

• Equity grants are a common component of executive compensation packages in the biotechnology industry.
• Companies like Gilead Sciences, Amgen, and Biogen also use stock options and restricted stock units to align executive incentives with shareholder value.
• The vesting schedules described in the document are fairly standard, with vesting occurring over a period of several years to encourage long-term commitment.

Stakeholder Impact

• Shareholders may view the equity grants positively as they incentivize management to increase shareholder value.
• Employees may see the grants as a sign of the company's commitment to its leadership.

Key Dates